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Abstract
Purpose : A recent report from the Laser in Glaucoma and Ocular Hypertension
(LiGHT) trial showed that selective laser trabeculoplasty (SLT) provides better clinical
effectiveness and lower treatment intensity among newly diagnosed glaucoma and
ocular hypertension (OHT) patients compared to intra-ocular pressure lowering eye
drops. The purpose of this secondary analysis of LiGHT data was to compare visual field
outcomes of OHT and glaucoma patients treated with Medicine-1  against those treated
with SLT (Laser-1 ).
Methods : Visual fields (VFs) for 344 patients (588 eyes) treated with Medicine-1  and
344 patients (590 eyes) treated with Laser-1  were measured using standard automated
perimetry and arranged in series (median length and duration: 9 VFs over 48 months).
Hierarchical linear models were used to estimate pointwise VF progression rates, which
were then averaged to produce a global progression estimate for each eye. Outcome
measures were pointwise and global progression rates of total deviation (TD) and
pattern deviation (PD). Proportions of points and patients in each treatment group with
fast (< -1 dB/y) or moderate (< -0.5 dB/y) progression were compared using log-
binomial regression.
Results : A greater proportion of eyes underwent moderate or fast TD progression in
the Medicine-1  group compared with the Laser-1  group (26.2% vs. 16.9%; Risk Ratio,
RR = 1.55 [1.23, 1.93], P < 0.001). A similar pattern was observed for pointwise rates
(Medicine-1  26.1% vs. Laser-1  19.0%, RR = 1.37 [1.33, 1.42], P < 0.001). A greater
proportion of pointwise PD rates were categorised as moderate or fast in the Medicine-
1  group (Medicine-1  11.5% vs. Laser-1  8.3%, RR = 1.39 [1.32, 1.46], P < 0.001).
Evidence for a difference in the proportion of eyes that underwent moderate or fast PD
progression was weaker (Medicine-1  9.9% vs. Laser-1  7.1%, RR = 1.39 [0.95, 2.03], P
= 0.0928).
Conclusions : Ocular hypertensive and glaucoma patients treated with Medicine-1
were more likely to undergo rapid VF progression than those treated with Laser-1 .
This is a 2020 ARVO Annual Meeting abstract.
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